Lonza is using the sale of its Capsules and Health Ingredients (CHI) unit to close the loop on its portfolio reset, while Lone Star Funds steps into a large, global carve-out with clear operational and governance levers.
Lone Star has agreed to acquire CHI for EUR 2,777.78 million, in a transaction recently announced. The deal supports Lonza’s stated objective to exit the segment and concentrate on its core contract development and manufacturing (CDMO) platforms.
Why this deal, why now
Lonza laid out its “One Lonza” plan in December 2024, signalling a sharper focus on its core business and a planned exit from CHI. Lonza has described the CHI divestment as the last and most significant step in its transformation into a pure-play CDMO.
For Lone Star, the entry point is a business with demonstrated demand and a broad end-market footprint. CHI returned to growth in 2025, reinforcing the view that the asset is not a declining non-core, but a scaled platform that can be run with dedicated ownership and investment.
Asset snapshot: a global platform with diversified demand
CHI operates across the Americas, Europe and Asia-Pacific, serving pharmaceutical, nutraceutical and consumer health customers. Its portfolio includes hard empty capsules, dosage form development platforms, and science-based nutritional ingredients.
That mix matters in underwriting because it can dampen single-end-market volatility, but it also raises integration and complexity questions for a financial sponsor taking over a global operation that previously sat inside a larger Swiss group.
Strategic rationale: Lonza sharpens its CDMO focus
By exiting CHI, Lonza intends to streamline operations and concentrate on core CDMO platforms including biologics manufacturing, advanced synthesis and specialised modalities. The strategic logic is straightforward: reduce management distraction, focus capex and technical talent on higher-priority CDMO capabilities, and present a cleaner equity story.
Lonza is not fully walking away economically. It is retaining a 40% stake in CHI with preferential participation in future exits, signalling continued confidence in the business’s stability and growth under new ownership.
Lonza has also stated that the total undiscounted value of proceeds from a full exit from CHI, including upfront proceeds and future participation, is expected to be at or above USD 4 billion. That structure frames the transaction as both a strategic divestment and a value-realisation programme, rather than a forced sale.
Lone Star’s playbook: carve-out execution and service continuity
Lone Star highlighted a commitment to maintaining high service quality and to uninterrupted operational delivery post-transaction. In a capsules and ingredients platform, customer retention is tied to quality systems, regulatory compliance, on-time-in-full performance and technical support. Any disruption can translate quickly into churn risk.
The sponsor’s historical positioning is to enhance portfolio companies by empowering management and investing for growth. For CHI, that suggests a familiar value-creation agenda, but the practical execution will hinge on carve-out readiness.
Key operational questions include:
- Separation scope and timing: which systems, shared services and supplier contracts need to be replicated or replaced post-close.
- Quality and regulatory continuity: how QA/QC governance and documentation are transferred without delays or compliance gaps.
- Commercial overlap and focus: whether CHI’s go-to-market teams have full autonomy and incentives aligned to standalone growth.
- Capex priorities: where investment goes first, capacity, automation, new product development, or margin protection.
Market signal: sponsor appetite for scaled healthcare carve-outs persists
This transaction reads as a with-trend signal in European healthcare: corporates keep sharpening focus around core platforms, while private equity continues to underwrite complex carve-outs where operational control can unlock value.
The combination of a large upfront consideration, Lonza’s retained minority stake, and a path to additional proceeds underscores a broader pattern: sellers increasingly structure exits to keep upside exposure, while buyers seek clarity on service continuity and standalone operating model from day one.
What to watch next
- Carve-out roadmap: timelines for ERP, quality systems and shared service separation.
- Management and governance: leadership depth and decision rights under Lone Star ownership.
- Customer retention metrics: any early signals on service levels and contract renewals post-close.
- Standalone capex plan: priorities for capacity, product development and manufacturing footprint.
- Future exit mechanics: how Lonza’s 40% stake and preferential participation shape timing and optionality for a subsequent liquidity event.